OBJECTIVE: Review the scientific evidence acquired in recent years on Prostate-Specific Antigen (PSA).
ACQUISITION OF EVIDENCE: Analysis of the available evidence on the current role of PSA, according to a panel of experts who recorded their experience on the subject.
SUMMARY OF THE EVIDENCE: Currently, PSA cannot be considered solely an indicator of the presence or absence of prostate cancer. Rather, the determination of PSA assists the urologist in indicating the most appropriate treatment for a patient with benign prostatic hypertrophic (BPH), as well as in suspecting a prostatic tumour when the PSA reading increases >0,3ng/ml, in patients treated with 5-alpha-reductase inhibitor, over the reading achieved at six months of having initiated this treatment. Moreover, PSA is a key factor in the follow-up of patients with prostate adenocarcinoma who undergo surgery, radiation therapy or minimally invasive techniques. PSA helps to define biochemical recurrence, suggest the existence of a local or distal recurrence and propose or rule out adjuvant therapies.
CONCLUSIONS: New data on the current role of PSA in the management of patients treated for BPH and/or prostate cancer should be taken into account.
Written by:
Hernández C, Morote J, Miñana B, Cózar JM. Are you the author?
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.
Reference: Actas Urol Esp. 2013 Apr 19. pii: S0210-4806(13)00036-3.
doi: 10.1016/j.acuro.2013.01.009
PubMed Abstract
PMID: 23608183
UroToday.com Prostate Cancer Section
